Dr. Matthew J. Frigault
Dr. Frigault is an oncologist and serves as the Clinical Director of the Cellular Immunotherapy Program, BMT & Cellular Therapy at Massachusetts General Hospital. He is also an Assistant Professor of Medicine at Harvard Medical School. His primary research efforts involve translating new and evolving cellular therapy products into patients while also gaining a better understanding of the immunologic mechanisms of efficacy, toxicity and resistance. Dr. Frigault’s work has included translational aspects of cellular therapy biology and signaling while at the University of Pennsylvania and development of next generation CAR-T cell constructs and their execution into first in human studies.
Dr. Frigault is also focused on understanding the role of cellular therapy in difficult patient populations, including those with active CNS disease, as well as understanding mechanisms of treatment limiting toxicities, mechanisms of resistance and identification of new and emerging adverse events not previously described. His goal to broaden the applicability of immune effector cell therapy to a wider array of patient populations and improve outcomes.